한국판 약물태도 척도의 심리측정적 특성 = Psychometric Properties of Korean Version of Drug Attitude Inventory(KDAI-10)

다국어 초록 (Multilingual Abstract)

Objective: The aim of this study was to test the psychometric properties of Korean version of 10 items of Drug Attitude Inventory (KDAI-10).
Methods: A total of 157 stabilized schizophrenic patients were entered into the study after completion of screening tests. They completed the KDAI-10. And then they were interviewed with various scales such as Subjective Response Scale (SRS), Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Side Effects Rating Scale (ESRS), and Global Assessment of Functioning (GAF). Correlations of KDAI-10 with these scales were tested.
Results: The Cronbach’s alpha used to measure the internal consistency of the scale, was high (0.83). Principal component analysis with varimax rotation produced 2 factors, which explained 50.37% of the total variances. The First factor including 6 items was the positive subjective feelings and the second factor including 4 items was the negative subjective feelings, which were identical to the original authors’. Individual item correlations with total scores were all statistically significant (r=0.48 ~ 0.72, p<.001). And correlations of KDAI-10 with SRS, PANSS, ESRS and GAF showed that they were significantly correlated.
Conclusion: Although the results were not quite satisfactory, KDAI-10 was demonstrated to have good reliability and construct validity.

참고문헌 (Reference)

1 윤진상, "항정신병약물치료하에서 주관적 안녕감을 평가하는 한국형 척도의 개발." 39 : 987-98, 2000

2 이중서, "한국판 양성 및 음성증후군 척도(Positive and Negative Syndrome Scale)의 신뢰도와 타당도" 대한신경정신의학회 40 (40): 1090-1105, 2001

3 류석환., "정신분열병 환자의 삶의 질: 항정신병약물의 차이에 따른 주관적 삶의 질 약물 태도와 약물 부작용의 관련성" 16 : 42-51, 2005

4 윤보현, "입원중인 정신분열병 환자에서 비전형 및 전형 항정신병약물에 대한 주관적인 반응" 대한생물치료정신의학회 8 (8): 298-304, 2002

5 김종훈, "비정형 항정신병약물을 투여 중인 정신분열병 환자의 주관적 삶의 질: 약물 부작용 및 약물에 대한 주관적 반응과의 관련성" 42 : 222-230, 2003

6 American Psychiatric Asociation, "The Diagnostic and Statisti-cal Manual of Mental Disorder" 1994

7 Awad AG, "Subjective response to neuroleptics in schizophrenia" 609-618, schizophrbul1993

8 "Subjective response to neuroleptics and the quality of life implications for treatment outcome" 27-32, actapsy-chatrscand1994

9 Hogan TP, "Subjective response to neuroleptics and outcome in schizophrenia a re-examination of two measures" 347-352, psycholmed1992

10 "Subjective response to antipsychotic drugs The spectrum of subjective effects of antipsychotic medication The role of dopamine in reward and pleasure behavior-review of data from preclinical research Brain imaging research on subjective responses to psychotropic drugs" 274 14 22-279 21 28, 187-190actaneuropsychiatrica2003actapsychiatrscand2005actapsychiatrscand2005

11 "Subjective response to anti-psychotic drugs failure to replicate predictions of outcome" 89-93, jclinpsychopharmacol1984

12 Van Putten T, "Subjective response as a predictor of outcome in pharmacotherapy" 477-480,

13 "Subjective neuroleptic response and treatment outcome under open and double-blind conditions-a preliminary report" 921-928,

14 Naber DA, "Self-rating scale to measure subjective effects of neuroleptic drugs relationships to objective psychopathology quality of life and other clinical variables" 123-133, intjclinpsychoph-arm1995

15 Weiden PJ, "Rating of Medication Influences scale in schizophrenia" hor-vitz-len (hor-vitz-len): 297-310, schizophrbul1994

16 "Quality of life of schizophrenic patients on medica-tions and implications for new drug trials" 262-265,

17 Awad AG, "Quality of life measurement in schizophrenia reconciling the quest for subjectivity with the question of reliability" 165-172,

18 Voruganti LNP, "Personal evaluation of transitions in treatment (PETiT) a scale to measure subjective tolerability of antipsychotic medications" 56 : 37-46, 2002

19 A theoretical psychodynamic explanation, "On the mechanism of action of neuroleptic drugs" 217-232, recadvbiolpsychiatry1963

20 Awad AG, "Neuroleptic dysphoria: revisiting the concept 50 years later" 111 (111): 6-13, 2005

21 Chouinard G, "Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS)." 76 : 247-265, 2005

22 McNair DM, "Manual for the profile of mood states" 1992

23 "Guy Chouinard와 Andre Ross-Chouin-ard의 추체외로증상 평가척도" 대한신경정신의학회 1996

24 "GAF report for the Global Assesment of Functioning Scale, window version : Users Manual" Toronto: Multi Health System INC 1996

25 "Flupenthixol versus risperidone: Subjective quality of life as an important factor for compliance in chronic schizophrenic patients." 37-203 46,

26 "Early subjective response and prediction of outcome to neuroleptic drug therapy in schi-zophrenia" 246-248,

27 "Dysphoric subjective response to neuroleptics in schizoph-renia: relationship to extrapyramidal side effects and sympto-matology" 14 : 405-409, 1999

28 Singh MM, "Dysphoric response to neuroleptic treatment in schi-zophrenia and its prognostic significance" disnervsyst1976191-196

29 Davidhizar RE, "Can clients with schizophrenia describe feelings and beliefs about taking medications? J Adv Neurol 1985" 469-473,

30 Hogan TP, "A self-report scale pre-dictive of drug compliance in schizophrenia" 177-183, psycholmed1983